PE20190335A1 - Receptores de celulas t - Google Patents
Receptores de celulas tInfo
- Publication number
- PE20190335A1 PE20190335A1 PE2018001971A PE2018001971A PE20190335A1 PE 20190335 A1 PE20190335 A1 PE 20190335A1 PE 2018001971 A PE2018001971 A PE 2018001971A PE 2018001971 A PE2018001971 A PE 2018001971A PE 20190335 A1 PE20190335 A1 PE 20190335A1
- Authority
- PE
- Peru
- Prior art keywords
- tcr
- alpha
- beta
- seq
- variable domain
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 abstract 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000012737 microarray-based gene expression Methods 0.000 abstract 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 230000009258 tissue cross reactivity Effects 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 108010012015 GVYDGREHTV Proteins 0.000 abstract 1
- 102000011786 HLA-A Antigens Human genes 0.000 abstract 1
- 108010075704 HLA-A Antigens Proteins 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Referido a receptores de celulas T (TCR) que tiene la propiedad de unirse a un complejo GVYDGREHTV (SEQ ID NO:1) HLA-A 02 y que comprende un dominio variable de cadena beta de TCR, en donde el domino variable de cadena alfa comprende una secuencia de aminoacidos que tiene al menos una identidad del 90% con los aminoacidos 1-113 de la SEQ ID NO:2, y/o el dominio variable de cadena beta comprende una secuencia de aminoacidos que tiene al menos una identidad del 90% con los aminoacidos 1-116 de la SEQ ID NO:3. Dichos TCR pueden comprender mutaciones no naturales dentro de los dominios variables alfa y/o beta con respecto a un TCR de MAGE A4 nativo. Dichos TCR pueden comprender mutaciones no naturales dentro de los dominios variables alfa y/o beta con respecto a un TCR de MAGE A4 nativo. Tambien se refiere a un acido nucleico que codifica una cadena alfa de TCR, un vector de expresion, una celula que alberga al vector, una celula no natural y/o purificada y/o modificada, una composicion farmaceutica y uso como nuevos reactivos inmunoterapeuticos para el tratamiento de enfermedades malignas
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606009 | 2016-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190335A1 true PE20190335A1 (es) | 2019-03-07 |
Family
ID=58548761
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001971A PE20190335A1 (es) | 2016-04-08 | 2017-04-07 | Receptores de celulas t |
| PE2023002239A PE20240693A1 (es) | 2016-04-08 | 2017-04-07 | Receptores de celulas t |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002239A PE20240693A1 (es) | 2016-04-08 | 2017-04-07 | Receptores de celulas t |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11505590B2 (es) |
| EP (2) | EP3440105B1 (es) |
| JP (1) | JP7254519B2 (es) |
| KR (1) | KR102473964B1 (es) |
| CN (1) | CN109563148B (es) |
| AU (2) | AU2017246693B2 (es) |
| BR (1) | BR112018070741A2 (es) |
| CL (1) | CL2018002859A1 (es) |
| CO (1) | CO2018011972A2 (es) |
| CR (1) | CR20180531A (es) |
| CY (1) | CY1125331T1 (es) |
| DK (1) | DK3440105T3 (es) |
| ES (1) | ES2914648T3 (es) |
| HR (1) | HRP20220865T1 (es) |
| HU (1) | HUE059159T2 (es) |
| IL (2) | IL308831A (es) |
| LT (1) | LT3440105T (es) |
| MA (1) | MA44608B1 (es) |
| MD (1) | MD3440105T2 (es) |
| MX (1) | MX2018012318A (es) |
| MY (1) | MY198621A (es) |
| PE (2) | PE20190335A1 (es) |
| PH (1) | PH12018502158B1 (es) |
| PL (1) | PL3440105T3 (es) |
| PT (1) | PT3440105T (es) |
| RS (1) | RS63371B1 (es) |
| SG (1) | SG11201808797XA (es) |
| SI (1) | SI3440105T1 (es) |
| SM (1) | SMT202200306T1 (es) |
| UA (1) | UA129144C2 (es) |
| WO (1) | WO2017175006A1 (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7204484B2 (ja) | 2016-04-08 | 2023-01-16 | アダプティミューン・リミテッド | Ｔ細胞受容体 |
| WO2017174822A1 (en) * | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
| CA3080546A1 (en) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| WO2019133443A1 (en) * | 2017-12-28 | 2019-07-04 | Janux Therapeutics, Inc. | Modified t cell receptors |
| GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
| EP3775238A1 (en) * | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| HRP20240176T1 (hr) | 2019-01-17 | 2024-04-12 | Immunocore Limited | Formulacije |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
| EP3714941A1 (en) * | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| CN114585646B (zh) * | 2019-06-18 | 2024-09-03 | 里珍纳龙药品有限公司 | Mage-a4 t细胞受体及其使用方法 |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| US12480958B2 (en) | 2019-08-13 | 2025-11-25 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:MHC binding polypeptides |
| GB201915282D0 (en) * | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| EP4076666A1 (en) | 2019-12-18 | 2022-10-26 | F. Hoffmann-La Roche AG | Antibodies binding to hla-a2/mage-a4 |
| EP4103285A2 (en) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| JP7785696B2 (ja) * | 2020-05-18 | 2025-12-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 操作されたｔ細胞受容体および使用の方法 |
| JP2023527293A (ja) * | 2020-05-19 | 2023-06-28 | アムジエン・インコーポレーテツド | Ｍａｇｅｂ２結合構築物 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022190007A1 (en) | 2021-03-09 | 2022-09-15 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries |
| CA3210289A1 (en) | 2021-03-09 | 2022-09-15 | Anna Maria SOBIERAJ | Mage-a4 peptide-mhc antigen binding proteins |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| TWI857377B (zh) | 2021-10-28 | 2024-10-01 | 美商基利科學股份有限公司 | 嗒-3(2h)-酮衍生物 |
| MX2024005066A (es) | 2021-10-29 | 2024-05-24 | Gilead Sciences Inc | Compuestos de cd73. |
| WO2023099606A1 (en) | 2021-12-01 | 2023-06-08 | Immunocore Limited | Treatment of mage-a4 positive cancer |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| PE20242225A1 (es) | 2022-03-17 | 2024-11-19 | Gilead Sciences Inc | Degradadores de dedos de zinc de la familia ikaros y usos de estos |
| AU2023256670A1 (en) | 2022-04-21 | 2024-10-17 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN117106060A (zh) * | 2022-05-17 | 2023-11-24 | 香雪生命科学技术（广东）有限公司 | 一种识别mage的高亲和力t细胞受体及其应用 |
| CA3260083A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | CD73 COMPOUNDS |
| WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| CN120112556A (zh) | 2022-08-18 | 2025-06-06 | 英美偌科有限公司 | 多结构域结合分子 |
| TW202413409A (zh) | 2022-08-18 | 2024-04-01 | 英商英美偌科有限公司 | 多域結合分子 |
| KR20250070621A (ko) | 2022-08-18 | 2025-05-20 | 이뮤노코어 리미티드 | Mage-a4에 특이적인 t 세포 수용체 융합 단백질 |
| AU2023342450A1 (en) | 2022-09-14 | 2025-03-13 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
| KR20250122479A (ko) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| GB202315181D0 (en) | 2023-10-03 | 2023-11-15 | Immunocore Ltd | Peptide-HLA binding molecules |
| TW202530269A (zh) * | 2023-10-27 | 2025-08-01 | 大陸商北京可瑞生物科技有限公司 | 基於ｔ細胞受體的多特異性多肽分子及其組合物和用途 |
| WO2025094054A1 (en) | 2023-11-01 | 2025-05-08 | Immunocore Limited | Method for purifying small multi-domain proteins |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| GB202320012D0 (en) | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6685698A (en) | 1997-03-07 | 1998-09-22 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
| CA2305630C (en) | 1997-10-02 | 2012-11-06 | Sunol Molecular Corporation | Soluble single-chain t-cell receptor proteins |
| EP1117679B9 (en) * | 1998-10-02 | 2010-07-07 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| ATE411522T1 (de) | 1999-12-06 | 2008-10-15 | Univ Illinois | Hochaffine t-zellrezeptorproteine und verfahren |
| WO2001062908A2 (en) | 2000-02-22 | 2001-08-30 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
| IL160359A0 (en) | 2001-08-31 | 2004-07-25 | Avidex Ltd | Soluble t cell receptor |
| AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| CA2501870C (en) | 2002-10-09 | 2013-07-02 | Avidex Limited | Single chain recombinant t cell receptors |
| WO2004044004A2 (en) | 2002-11-09 | 2004-05-27 | Avidex Limited | T cell receptor display |
| GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| EP2301964A1 (en) | 2005-04-01 | 2011-03-30 | Immunocore Ltd. | High affinity HIV T cell receptors |
| CN101287831B (zh) * | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| JP6415322B2 (ja) | 2011-09-15 | 2018-10-31 | アメリカ合衆国 | Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体 |
| CN104144700B (zh) * | 2011-10-14 | 2016-10-19 | 特瓦制药澳大利亚私人有限公司 | 抗CD1d的抗体 |
| LT3424947T (lt) | 2011-10-28 | 2021-03-10 | Regeneron Pharmaceuticals, Inc. | Genetiškai modifikuotos t ląstelių receptorių pelės |
| GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
| US10377808B2 (en) * | 2013-01-29 | 2019-08-13 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch | High avidity antigen recognizing constructs |
| CA2906587C (en) | 2013-03-13 | 2023-02-14 | Health Research, Inc. | Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen |
| US10927160B2 (en) * | 2014-07-09 | 2021-02-23 | The Regents Of The University Of California | Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof |
| CN107074970B (zh) | 2014-08-04 | 2021-07-30 | 弗雷德哈钦森癌症研究中心 | 特异性针对wt-1的t细胞免疫疗法 |
| ES2807591T3 (es) | 2015-04-13 | 2021-02-23 | Pfizer | Receptores de antígeno quimérico dirigidos a antígeno de maduración de células B |
| DK3430030T5 (da) | 2016-03-16 | 2024-09-23 | Immatics Biotechnologies Gmbh | Transficerede t-celler og t-cellereceptorer til anvendelse i immunoterapi mod cancer |
| IL261941B2 (en) | 2016-04-01 | 2023-11-01 | Kite Pharma Inc | Chimeric antigen and T cell receptors and methods of use |
-
2017
- 2017-04-07 MY MYPI2018001690A patent/MY198621A/en unknown
- 2017-04-07 PL PL17717845.6T patent/PL3440105T3/pl unknown
- 2017-04-07 IL IL308831A patent/IL308831A/en unknown
- 2017-04-07 SG SG11201808797XA patent/SG11201808797XA/en unknown
- 2017-04-07 MD MDE20190184T patent/MD3440105T2/ro unknown
- 2017-04-07 ES ES17717845T patent/ES2914648T3/es active Active
- 2017-04-07 AU AU2017246693A patent/AU2017246693B2/en active Active
- 2017-04-07 CR CR20180531A patent/CR20180531A/es unknown
- 2017-04-07 CN CN201780035758.0A patent/CN109563148B/zh active Active
- 2017-04-07 HU HUE17717845A patent/HUE059159T2/hu unknown
- 2017-04-07 SM SM20220306T patent/SMT202200306T1/it unknown
- 2017-04-07 JP JP2018552859A patent/JP7254519B2/ja active Active
- 2017-04-07 LT LTEPPCT/GB2017/050985T patent/LT3440105T/lt unknown
- 2017-04-07 PE PE2018001971A patent/PE20190335A1/es unknown
- 2017-04-07 MX MX2018012318A patent/MX2018012318A/es unknown
- 2017-04-07 HR HRP20220865TT patent/HRP20220865T1/hr unknown
- 2017-04-07 EP EP17717845.6A patent/EP3440105B1/en active Active
- 2017-04-07 UA UAA201810441A patent/UA129144C2/uk unknown
- 2017-04-07 PT PT177178456T patent/PT3440105T/pt unknown
- 2017-04-07 BR BR112018070741-4A patent/BR112018070741A2/pt not_active Application Discontinuation
- 2017-04-07 WO PCT/GB2017/050985 patent/WO2017175006A1/en not_active Ceased
- 2017-04-07 PH PH1/2018/502158A patent/PH12018502158B1/en unknown
- 2017-04-07 EP EP21211000.1A patent/EP4023668A1/en active Pending
- 2017-04-07 KR KR1020187032374A patent/KR102473964B1/ko active Active
- 2017-04-07 MA MA44608A patent/MA44608B1/fr unknown
- 2017-04-07 IL IL262144A patent/IL262144B2/en unknown
- 2017-04-07 PE PE2023002239A patent/PE20240693A1/es unknown
- 2017-04-07 SI SI201731151T patent/SI3440105T1/sl unknown
- 2017-04-07 DK DK17717845.6T patent/DK3440105T3/da active
- 2017-04-07 RS RS20220652A patent/RS63371B1/sr unknown
- 2017-04-07 US US16/092,174 patent/US11505590B2/en active Active
-
2018
- 2018-10-08 CL CL2018002859A patent/CL2018002859A1/es unknown
- 2018-11-02 CO CONC2018/0011972A patent/CO2018011972A2/es unknown
-
2022
- 2022-07-05 CY CY20221100457T patent/CY1125331T1/el unknown
- 2022-10-13 US US18/046,408 patent/US20230322895A1/en active Pending
- 2022-10-19 AU AU2022256131A patent/AU2022256131A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190335A1 (es) | Receptores de celulas t | |
| ZA202306640B (en) | T cell receptors | |
| MX2025007532A (es) | Receptores de antigenos quimericos para el tratamiento del cancer | |
| CL2020001181A1 (es) | Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos. | |
| MX2019006727A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
| CR20180492A (es) | Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer | |
| MX395287B (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| MX2018007621A (es) | Receptores de celulas t. | |
| NZ715038A (en) | T cell receptors | |
| UY36539A (es) | Proteínas de unión a icos | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| CL2019003426A1 (es) | Nuevos péptidos (seq id n°174), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
| CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| PE20230321A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
| PE20180505A1 (es) | Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres | |
| BR112017000939A2 (pt) | tratamento de câncer usando um receptor antigênico quimérico de cll-1 | |
| PE20191248A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
| ES2721159T3 (es) | Antígenos asociados a tumor independientes de MHC novedosos | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины | |
| PE20190967A1 (es) | Aislados modificados de streptomyces fungicidicus y su uso | |
| CO2019006926A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
| AR110504A1 (es) | Receptores de células t y terapia inmunológica que los utiliza | |
| AR104967A1 (es) | Polinucleótido aislado, vector recombinante, adenovirus recombinante y composición que lo comprenden y su uso para preparar un medicamento |